annual EBITDA:
$9.11B+$410.22M(+4.71%)Summary
- As of today (August 17, 2025), TAK annual EBITDA is $9.11 billion, with the most recent change of +$410.22 million (+4.71%) on March 1, 2025.
- During the last 3 years, TAK annual EBITDA has fallen by -$1.51 billion (-14.23%).
- TAK annual EBITDA is now -14.23% below its all-time high of $10.62 billion, reached on March 31, 2022.
Performance
TAK EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$3.04B+$2.56B(+531.70%)Summary
- As of today (August 17, 2025), TAK quarterly EBITDA is $3.04 billion, with the most recent change of +$2.56 billion (+531.70%) on June 1, 2025.
- Over the past year, TAK quarterly EBITDA has increased by +$546.25 million (+21.92%).
- TAK quarterly EBITDA is now -23.89% below its all-time high of $3.99 billion, reached on June 30, 2021.
Performance
TAK quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$7.69B+$546.25M(+7.65%)Summary
- As of today (August 17, 2025), TAK TTM EBITDA is $7.69 billion, with the most recent change of +$546.25 million (+7.65%) on June 1, 2025.
- Over the past year, TAK TTM EBITDA has increased by +$633.12 million (+8.98%).
- TAK TTM EBITDA is now -32.15% below its all-time high of $11.33 billion, reached on September 30, 2021.
Performance
TAK TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TAK EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.7% | +21.9% | +9.0% |
| 3 y3 years | -14.2% | +6.6% | -4.5% |
| 5 y5 years | +11.8% | +2.6% | +3.3% |
TAK EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -14.2% | +4.7% | at high | +531.7% | -14.7% | +9.0% |
| 5 y | 5-year | -14.2% | +11.8% | -23.9% | +531.7% | -32.1% | +9.0% |
| alltime | all time | -14.2% | +1491.7% | -23.9% | +246.4% | -32.1% | +1098.3% |
TAK EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $3.04B(+531.7%) | $7.69B(+7.7%) |
| Mar 2025 | $9.11B(+4.7%) | $481.00M(-70.0%) | $7.14B(-1.4%) |
| Dec 2024 | - | $1.61B(-37.3%) | $7.24B(-11.9%) |
| Sep 2024 | - | $2.56B(+2.7%) | $8.21B(+16.4%) |
| Jun 2024 | - | $2.49B(+329.6%) | $7.05B(-2.4%) |
| Mar 2024 | $8.70B(-10.9%) | $580.08M(-77.5%) | $7.23B(-11.4%) |
| Dec 2023 | - | $2.58B(+84.2%) | $8.16B(-0.0%) |
| Sep 2023 | - | $1.40B(-47.5%) | $8.16B(-7.6%) |
| Jun 2023 | - | $2.67B(+76.6%) | $8.83B(-2.0%) |
| Mar 2023 | $9.76B(-8.1%) | $1.51B(-41.5%) | $9.01B(+10.4%) |
| Dec 2022 | - | $2.58B(+24.6%) | $8.17B(+3.0%) |
| Sep 2022 | - | $2.07B(-27.3%) | $7.93B(-1.6%) |
| Jun 2022 | - | $2.85B(+329.3%) | $8.05B(-12.4%) |
| Mar 2022 | $10.62B(+11.8%) | $663.84M(-71.6%) | $9.19B(-13.9%) |
| Dec 2021 | - | $2.34B(+6.6%) | $10.68B(-5.7%) |
| Sep 2021 | - | $2.20B(-45.0%) | $11.33B(+3.0%) |
| Jun 2021 | - | $3.99B(+85.7%) | $11.00B(+10.3%) |
| Mar 2021 | $9.50B(+16.5%) | $2.15B(-28.1%) | $9.97B(+19.9%) |
| Dec 2020 | - | $2.99B(+60.2%) | $8.31B(+14.1%) |
| Sep 2020 | - | $1.87B(-37.0%) | $7.29B(-2.1%) |
| Jun 2020 | - | $2.96B(+497.1%) | $7.44B(+17.0%) |
| Mar 2020 | $8.15B(+93.8%) | $496.04M(-74.7%) | $6.36B(-0.4%) |
| Dec 2019 | - | $1.96B(-3.0%) | $6.38B(+18.6%) |
| Sep 2019 | - | $2.02B(+7.6%) | $5.38B(+22.5%) |
| Jun 2019 | - | $1.88B(+261.5%) | $4.40B(+13.7%) |
| Mar 2019 | $4.21B(+23.5%) | $519.95M(-45.8%) | $3.87B(+31.5%) |
| Dec 2018 | - | $959.76M(-7.3%) | $2.94B(-0.8%) |
| Sep 2018 | - | $1.04B(-23.3%) | $2.96B(+8.8%) |
| Jun 2018 | - | $1.35B(-432.7%) | $2.72B(-25.6%) |
| Mar 2018 | $3.41B(+42.7%) | -$405.73M(-141.3%) | $3.66B(-5.8%) |
| Dec 2017 | - | $982.45M(+23.5%) | $3.89B(+1.5%) |
| Sep 2017 | - | $795.78M(-65.2%) | $3.83B(+2.0%) |
| Jun 2017 | - | $2.29B(-1376.8%) | $3.75B(+13.5%) |
| Mar 2017 | $2.39B(-18.9%) | -$179.14M(-119.4%) | $3.31B(-9.5%) |
| Dec 2016 | - | $924.59M(+28.6%) | $3.65B(+0.3%) |
| Sep 2016 | - | $718.97M(-61.0%) | $3.64B(-5.9%) |
| Jun 2016 | - | $1.84B(+999.9%) | $3.87B(+34.3%) |
| Mar 2016 | $2.94B(-16.6%) | $167.39M(-81.7%) | $2.88B(+349.7%) |
| Dec 2015 | - | $915.45M(-3.5%) | $641.37M(-47.2%) |
| Sep 2015 | - | $948.47M(+11.2%) | $1.21B(-7.8%) |
| Jun 2015 | - | $853.05M(-141.1%) | $1.32B(-17.8%) |
| Mar 2015 | $3.53B | -$2.08B(-239.5%) | $1.60B(-61.4%) |
| Dec 2014 | - | $1.49B(+41.5%) | $4.15B(+4.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2014 | - | $1.05B(-7.7%) | $3.98B(-3.4%) |
| Jun 2014 | - | $1.14B(+140.7%) | $4.12B(+1.4%) |
| Mar 2014 | $3.32B(+10.1%) | $473.05M(-64.0%) | $4.06B(+18.5%) |
| Dec 2013 | - | $1.32B(+10.5%) | $3.43B(+33.9%) |
| Sep 2013 | - | $1.19B(+9.9%) | $2.56B(+23.4%) |
| Jun 2013 | - | $1.08B(-778.0%) | $2.07B(+6.6%) |
| Mar 2013 | $3.02B(-42.6%) | -$159.71M(-135.7%) | $1.95B(+12.3%) |
| Dec 2012 | - | $447.83M(-36.4%) | $1.73B(-22.5%) |
| Sep 2012 | - | $703.99M(-26.2%) | $2.24B(-17.1%) |
| Jun 2012 | - | $954.50M(-356.2%) | $2.70B(-15.9%) |
| Mar 2012 | $5.26B(-5.0%) | -$372.52M(-139.1%) | $3.21B(-26.8%) |
| Dec 2011 | - | $952.55M(-18.3%) | $4.39B(-13.7%) |
| Sep 2011 | - | $1.17B(-20.4%) | $5.08B(-9.7%) |
| Jun 2011 | - | $1.47B(+82.5%) | $5.63B(+0.9%) |
| Mar 2011 | $5.53B(-4.0%) | $802.86M(-51.3%) | $5.58B(-0.1%) |
| Dec 2010 | - | $1.65B(-3.7%) | $5.59B(+1.1%) |
| Sep 2010 | - | $1.71B(+21.2%) | $5.53B(+2.5%) |
| Jun 2010 | - | $1.41B(+74.3%) | $5.39B(-5.5%) |
| Mar 2010 | $5.76B(+36.5%) | $811.00M(-49.0%) | $5.70B(-4.7%) |
| Dec 2009 | - | $1.59B(+0.7%) | $5.99B(-5.0%) |
| Sep 2009 | - | $1.58B(-8.6%) | $6.30B(+9.7%) |
| Jun 2009 | - | $1.73B(+57.9%) | $5.75B(+43.0%) |
| Mar 2009 | $4.22B(+6.1%) | $1.09B(-42.6%) | $4.02B(+37.4%) |
| Dec 2008 | - | $1.91B(+87.0%) | $2.92B(+187.0%) |
| Sep 2008 | - | $1.02B | $1.02B |
| Mar 2008 | $3.98B(-4.5%) | - | - |
| Mar 2007 | $4.17B(+9.3%) | - | - |
| Mar 2006 | $3.81B(-1.6%) | - | - |
| Mar 2005 | $3.87B(+9.5%) | - | - |
| Mar 2004 | $3.54B(+26.6%) | - | - |
| Mar 2003 | $2.79B(+12.8%) | - | - |
| Mar 2002 | $2.48B(+5.5%) | - | - |
| Mar 2001 | $2.35B(+27.7%) | - | - |
| Mar 2000 | $1.84B(+33.6%) | - | - |
| Mar 1999 | $1.38B(+16.1%) | - | - |
| Mar 1998 | $1.19B(-15.7%) | - | - |
| Mar 1997 | $1.41B(-7.1%) | - | - |
| Mar 1996 | $1.51B(+19.1%) | - | - |
| Mar 1995 | $1.27B(+71.1%) | - | - |
| Mar 1994 | $743.36M(+29.9%) | - | - |
| Mar 1993 | $572.38M(-19.4%) | - | - |
| Mar 1992 | $709.98M(+22.1%) | - | - |
| Mar 1991 | $581.40M | - | - |
FAQ
- What is Takeda Pharmaceutical Company Limited annual EBITDA?
- What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
- What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA?
- What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
- What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
What is Takeda Pharmaceutical Company Limited annual EBITDA?
The current annual EBITDA of TAK is $9.11B
What is the all time high annual EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high annual EBITDA is $10.62B
What is Takeda Pharmaceutical Company Limited annual EBITDA year-on-year change?
Over the past year, TAK annual EBITDA has changed by +$410.22M (+4.71%)
What is Takeda Pharmaceutical Company Limited quarterly EBITDA?
The current quarterly EBITDA of TAK is $3.04B
What is the all time high quarterly EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high quarterly EBITDA is $3.99B
What is Takeda Pharmaceutical Company Limited quarterly EBITDA year-on-year change?
Over the past year, TAK quarterly EBITDA has changed by +$546.25M (+21.92%)
What is Takeda Pharmaceutical Company Limited TTM EBITDA?
The current TTM EBITDA of TAK is $7.69B
What is the all time high TTM EBITDA for Takeda Pharmaceutical Company Limited?
Takeda Pharmaceutical Company Limited all-time high TTM EBITDA is $11.33B
What is Takeda Pharmaceutical Company Limited TTM EBITDA year-on-year change?
Over the past year, TAK TTM EBITDA has changed by +$633.12M (+8.98%)